Share this @internewscast.com

The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well.

While Mounjaro had already been used by some patients “off-label” for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too.

Zepbound will be available for patients in the U.S. by the end of the year, the drugmaker said.

The company said Wednesday in a news release that the medication, administered with an injection pen, will be sold at a cheaper list price than its semaglutide competitors from Novo Nordisk, which are branded as Wegovy for weight loss and Ozempic for diabetes. 

“New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management,” Joe Nadglowski, CEO of the Obesity Action Coalition, said in Eli Lilly’s release. The group receives funding from Eli Lilly and other pharmaceutical and health care companies.

The FDA’s approval of Zepbound was partially based on a trial of adults without diabetes, which found that participants — who averaged 231 pounds at the start of the trial — who were given the highest approved dose lost around 18% of their body weight compared to placebo.

zepbound.jpg
The FDA approved Eli Lilly’s drug Zepbound for weight loss.

Eli Lilly


“In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need,” the FDA’s Dr. John Sharretts, director of the agency’s Division of Diabetes, Lipid Disorders, and Obesity, said in a news release.

While there have not been results from large clinical trials comparing Novo Nordisk’s and Eli Lilly’s medications head-to-head, there is some research to suggest Zepboud could outperform Ozempic

A meta-analysis presented at the annual meeting of the European Association for the Study of Diabetes in October concluded tirzepatide was “more effective for weight loss than semaglutide, with a larger weight-loss effect at higher doses,” but acknowledged limitations in trying to make a direct comparisons of the two.

In a report earlier this year comparing semaglutide and tirzepatide for diabetics, the Institute for Clinical and Economic Review concluded that tirzepatide showed “greater reduction” in weight and other key markers, but “had a greater incidence of gastrointestinal side effects, severe adverse events, and discontinuation compared with semaglutide.”

Zepbound carries the risk of an array of potential side effects, the FDA says, including nausea, diarrhea, vomiting, constipation, and hair loss. 

Like with other weight loss drugs in this class, some of Zepbound’s side effects could be serious.  

People with a history of severe gastroparesis, or stomach paralysis, should not use the drug, the FDA says. 

Eli Lilly and Novo Nordisk have both faced claims that their drugs can cause stomach paralysis. The FDA recently moved to acknowledge reports of ileus, or a blockage in the intestines, on Ozempic’s label.

The agency also notes that other people could be at higher risk of more severe issues from Zepbound, including patients with a history of medullary thyroid cancer, pancreas inflammation, or severe gastrointestinal disease.

It also should not be combined with other so-called GLP-1 receptor agonist drugs, which include its sibling Mounjaro, as well as Wegovy and Ozempic. 

“The safety and effectiveness of coadministration of Zepbound with other medications for weight management have not been established,” the agency says.

Share this @internewscast.com
You May Also Like

Teen Baldness Shattered My Confidence Until I Found a Life-Changing Hair Loss Solution—And It’s Not a Transplant! Bet You Can’t Guess What It Is!

Young men affected by hair loss are increasingly turning to a baldness…

Cardiologist Warns: Elbow Pain Might Indicate a Serious Health Problem

A cardiologist has revealed a little-known symptom that could signal a serious…

A Gut Specialist Alerts to a ‘Timebomb’ Cancer Risk Affecting Millions, and Shares a Simple Prevention Method

A gut health doctor has revealed a surprising cause of a deadly cancer on…

Top 30 Sleep Habits of Brits Unveiled – from Avoiding Cheese to Counting Sheep

Brits are going to great lengths for a blissful night’s slumber, from…

5 Common Medications That Require Urgent Action to Prevent Heatwave Issues

An alert has been issued to anyone who takes five different kinds…

The Alarming Reality of Alternative Cancer Therapies: My Encounter with ‘Coaches’ Selling Treatments that Risk Lives, Especially for Young Women like Paloma – LIZ O’RIORDAN

The message, from a stranger on Instagram, absolutely broke me. ‘Dear Liz,’…

I Experience Unexplained Heart Palpitations Despite Normal ECG Results – What Could Be the Cause? Dr. Ellie Explains

I have had heart palpitations on and off for some time. I’ve…

Small 50-Calorie Reduction Could Help 2 Million Adults Overcome Obesity, According to DHSC

The Department of Health and Social Care has introduced new food standards,…

Brits Advised Against Consuming Coffee This Monday

Staying cool in the UK during a heatwave can be a tricky…

“Stay Cool Tonight: Enhance Your Fan’s Performance in 3 Easy Steps”

With temperatures set to be a stuffy 20C tonight for large parts…

New UK Prostate Cancer Test May Eliminate Biopsies for 80% of Men

A British-made prostate cancer test could avoid the need for biopsies in…

I consumed a trendy “health” food daily to shed pounds, but it turned out to be toxic.

Nasha Montgomery was looking to lose weight and began following a healthy diet,…